Paul Meister Net Worth

The estimated Net Worth of Paul M Meister is at least $6.39 Milione dollars as of 10 May 2024. Mr. Meister owns over 107,034 units of Amneal Pharmaceuticals Inc stock worth over $6,083,505 and over the last 22 years he sold AMRX stock worth over $0. In addition, he makes $305,774 as Independent Chairman of the Board at Amneal Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Meister AMRX stock SEC Form 4 insiders trading

Paul has made over 32 trades of the Amneal Pharmaceuticals Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently he exercised 107,034 units of AMRX stock worth $894,804 on 10 May 2024.

The largest trade he's ever made was buying 353,649 units of Amneal Pharmaceuticals Inc stock on 17 March 2020 worth over $968,998. On average, Paul trades about 18,310 units every 81 days since 2003. As of 10 May 2024 he still owns at least 727,692 units of Amneal Pharmaceuticals Inc stock.

You can see the complete history of Mr. Meister stock trades at the bottom of the page.

Paul Meister biography

Paul M. Meister serves as Independent Chairman of the Board of the Company. Mr. Meister served as Chairman and CEO of inVentiv Health (now Syneos Health), a leading provider of commercial, consulting and clinical research services to the pharmaceutical and biotech industries. Mr. Meister was Chairman of Thermo Fisher Scientific, Inc., a scientific instruments equipment and supplies company, from November 2006 to April 2007. He was previously Vice Chairman of Fisher Scientific International, Inc., a predecessor of Thermo Fisher Scientific, Inc., from 2001 to 2006, and Chief Financial Officer of Fisher Scientific International, Inc. from 1991 to 2001. Earlier in his career, Mr. Meister served in a number of executive leadership positions at Wheelabrator Technologies Inc., The Henley Group Inc., and AlliedSignal Inc. (now Honeywell International, Inc.). He began his career with Ford Motor Company. Mr. Meister holds a bachelor of arts degree from the University of Michigan and a master of business administration from Northwestern University. He currently serves as a director on the boards of Aptiv PLC, Quanterix Corporation, Oaktree Acquisition Corp. and Scientific Games Corporation. He previously served as a director of vTv Therapeutics and LKQ Corporation until 2018 and as a director of Revlon until 2019.

What is the salary of Paul Meister?

As the Independent Chairman of the Board of Amneal Pharmaceuticals Inc, the total compensation of Paul Meister at Amneal Pharmaceuticals Inc is $305,774. There are 13 executives at Amneal Pharmaceuticals Inc getting paid more, with Andrew Boyer having the highest compensation of $3,113,080.

How old is Paul Meister?

Paul Meister is 67, he's been the Independent Chairman of the Board of Amneal Pharmaceuticals Inc since 2019. There are no older and 21 younger executives at Amneal Pharmaceuticals Inc.

What's Paul Meister's mailing address?

Paul's mailing address filed with the SEC is C/O QUANTERIX CORPORATION,, 900 MIDDLESEX TURNPIKE, BILLERICA, MA, 01821.

Insiders trading at Amneal Pharmaceuticals Inc

Over the last 7 years, insiders at Amneal Pharmaceuticals Inc have traded over $867,197,480 worth of Amneal Pharmaceuticals Inc stock and bought 3,818,425 units worth $12,997,905 . The most active insiders traders include Gp A, Llcbonderman Davidcou..., Holdings, Llc Aphc e International Ltd Fosun. On average, Amneal Pharmaceuticals Inc executives and independent directors trade stock every 18 days with the average trade being worth of $3,857,739. The most recent stock trade was executed by Andrew S Boyer on 14 August 2024, trading 62,711 units of AMRX stock currently worth $491,654.

What does Amneal Pharmaceuticals Inc do?

an american pharmaceutical company, amneal develops and produces affordable medicines. the company was built upon a family tradition of quality and integrity. everything amneal does, across the full spectrum of its business, is in service to these guiding principles. amneal is committed to constantly elevating and refining the value it delivers to its customers and patients around the globe.

Complete history of Mr. Meister stock trades at LKQ Corp, Scientific Games, Minerals Technologies, Thermo Fisher Scientific, Quanterix Corp, Aptiv PLC, Amneal Pharmaceuticals Inc e Telesis Bio Inc

Amneal Pharmaceuticals Inc executives and stock owners

Amneal Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Andrew Boyer,
  Executive Vice President - Commercial Operations
• Chintu Patel R.Ph, R.Ph.,
  Co-Founder, Co-CEO & Director
• Nikita Shah,
  Chief Human Resource Officer, Senior Vice President
• Andrew S. Boyer,
  Exec. VP & Chief Commercial Officer of Generics
• Anastasios G. Konidaris,
  Exec. VP & CFO
• Joseph Todisco MBA,
  Exec. VP & Chief Commercial Officer of Specialty
• Nikita Shah,
  Exec. VP and Chief HR Officer & Strategic Planning Officer
• J. Kevin Buchi,
  Independent Director
• Ted Nark,
  Independent Director
• Emily Alva,
  Independent Director
• Gautam Patel,
  Director
• Chintu Patel,
  Co-Chief Executive Officer, Co-Founder, Director
• Chirag Patel,
  President, Co-Chief Executive Officer, Director
• Paul Meister,
  Independent Chairman of the Board
• Shlomo Yanai,
  Independent Director
• John Kiely,
  Independent Director
• Jeffrey George,
  Independent Director
• Chintu Patel R.Ph., R.Ph,
  Co-Founder, Co-CEO & Director
• Chirag K. Patel,
  Co-Founder, Co-CEO, Pres & Director
• Joseph Todisco,
  Senior Vice President - Specialty Commercial
• Apurva Saraf,
  Senior Vice President - Corporate Development
• Joseph Greer,
  Senior Vice President - Global Quality Management
• Stephen Manzano,
  Senior Vice President, General Counsel & Corporate Secretary
• Sanjay Jain,
  President - India
• Anastasios Konidaris,
  Chief Financial Officer, Senior Vice President
• Jason B. Daly Esq.,
  Sr. VP, Chief Legal Officer & Corp. Sec.
• Dr. Nikunj Patel,
  Head of Ops & Exec. VP of Amneal Pharmaceuticals (India) Pvt Ltd
• Sanjiv Patel,
  Sr. VP of Operations
• Stephen J. Manzano,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Anthony DiMeo,
  Sr. Director of Investor Relations
• Sheldon Hirt,
  SVP, GC & Corp. Sec.
• Jean Selden Greene,
  Director
• Holdings, Llc Aphc,
  10% owner
• Robert L Burr,
  Director
• Bryan M. Reasons,
  CFO
• Robert A Stewart,
  President and CEO
• Dharmendra Rama,
  Director
• Janet S. Vergis,
  Director
• Peter R Terreri,
  Director
• Paul Bisaro,
  Executive Chairman
• David A Buchen,
  SVP, Chief Legal Officer
• Todd P. Branning,
  SVP and CFO
• Pradeep Bhadauria,
  SVP, Chief Scientific Officer
• International Ltd Fosun,
  10% owner
• Gustavo Pesquin,
  See Remarks
• Gp A, Llcbonderman Davidcou...,
  
• Tasos Konidaris,
  Executive Vice President & CFO
• Jason B. Daly,
  SVP, Chief Legal Officer
• Deborah M. Autor,
  Director
• Dipan Patel,
  
• Tushar Bhikhubhai Patel,
  10% owner